Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging

Circulation

Volumn 140, Issue 4, 2019, Pages 303-315

  Kidokoro, Kengo ^a   Cherney, David Z I ^b   Bozovic, Andrea ^b   Nagasu, Hajime ^a   Satoh, Minoru ^a   Kanda, Eiichiro ^a   Sasaki, Tamaki ^a   Kashihara, Naoki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adenosine; feedback; hemodynamics; physiological; sodium glucose transporter 2 inhibitors

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 7 NITROINDAZOLE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ALBUMIN; EMPAGLIFLOZIN; GLUCOSE; INSULIN; NITRIC OXIDE; PROSTAGLANDIN E2; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; DRUG URINE LEVEL; FEEDBACK SYSTEM; GLOMERULUS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; MOUSE; MULTIPHOTON MICROSCOPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENAL PROTECTION; SINGLE DRUG DOSE; SINGLE NEPHRON GLOMERULAR FILTRATION RATE; SODIUM URINE LEVEL; TELEMETRY; TUBULOGLOMERULAR FEEDBACK; URINARY EXCRETION; ANIMAL; DIAGNOSTIC IMAGING; EXPERIMENTAL DIABETES MELLITUS; HUMAN; IN VITRO STUDY; KIDNEY; PATHOPHYSIOLOGY; PHARMACOLOGY; PROCEDURES;

ANIMALS; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSIDES; HUMANS; IN VITRO TECHNIQUES; KIDNEY; MALE; MICE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85066099304     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.037418     Document Type: Article

References (50)

1. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017; 136: 1643-1658. doi: 10.1161/CIRCULATIONAHA.117.030012
2. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016; 134: 752-772. doi: 10.1161/CIRCULATIONAHA. 116.021887
3. McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic kidney disease in diabetes. Can J Diabetes. 42(suppl 1): S201-S209.
4. Goldenberg RM, Berall M, Chan CTM, Cherney DZI, Lovshin JA, McFarlane PA, Senior PA, Verma S, Weinstein JJ. Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new. Can J Diabetes. 2018; 42: 325-334. doi: 10.1016/j.jcjd.2017.06.008
5. Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Renal Physiol. 2015; 308: F1343-F1357. doi: 10.1152/ajprenal.00007.2015
6. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 2099. doi: 10.1056/NEJMc1712572
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720
8. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323-334. doi: 10.1056/NEJMoa1515920
9. Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, et al; GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012; 35: 2061-2068. doi: 10.2337/dc11-2189
10. Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes. 2012; 3: 1-6. doi: 10.4239/wjd.v3.i1.1
11. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010; 53: 2093-2104. doi: 10.1007/s00125-010-1794-9
12. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-597. doi: 10.1161/CIRCULATIONAHA.113.005081
13. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999; 10: 2569-2576.
14. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014; 306: F194-F204. doi: 10.1152/ajprenal.00520.2013
15. Yang T, Singh I, Pham H, Sun D, Smart A, Schnermann JB, Briggs JP. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol. 1998; 274(3 pt 2): F481-F489.
16. Komers R, Lindsley JN, Oyama TT, Allison KM, Anderson S. Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am J Physiol Renal Physiol. 2000; 279: F573-F583. doi: 10.1152/ajprenal.2000.279.3.F573
17. Shin SJ, Lai FJ, Wen JD, Hsiao PJ, Hsieh MC, Tzeng TF, Chen HC, Guh JY, Tsai JH. Neuronal and endothelial nitric oxide synthase expression in outer medulla of streptozotocin-induced diabetic rat kidney. Diabetologia. 2000; 43: 649-659. doi: 10.1007/s001250051354
18. Rajasekeran H, Lytvyn Y, Bozovic A, Lovshin JA, Diamandis E, Cattran D, Husain M, Perkins BA, Advani A, Reich HN, et al. Urinary adenosine excretion in type 1 diabetes. Am J Physiol Renal Physiol. 2017; 313: F184-F191. doi: 10.1152/ajprenal.00043.2017
19. Kang JJ, Toma I, Sipos A, McCulloch F, Peti-Peterdi J. Quantitative imaging of basic functions in renal (patho)physiology. Am J Physiol Renal Physiol. 2006; 291: F495-F502. doi: 10.1152/ajprenal.00521.2005
20. Satoh M, Kobayashi S, Kuwabara A, Tomita N, Sasaki T, Kashihara N. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats. Microcirculation. 2010; 17: 103-112. doi: 10.1111/j.1549-8719.2009.00010.x
21. Kuwabara A, Satoh M, Tomita N, Sasaki T, Kashihara N. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia. 2010; 53: 2056-2065. doi: 10.1007/s00125-010-1810-0
22. Kidokoro K, Satoh M, Channon KM, Yada T, Sasaki T, Kashihara N. Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy. J Am Soc Nephrol. 2013; 24: 1139-1150. doi: 10.1681/ASN.2012080783
23. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013; 304: F156-F167. doi: 10.1152/ajprenal. 00409.2012
24. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014; 66: 975-987. doi: 10.1111/jphp.12223
25. Škrtic M, Lytvyn Y, Yang GK, Yip P, Lai V, Silverman M, Cherney DZ. Glomerular haemodynamic profile of patients with type 1 diabetes compared with healthy control subjects. Diabet Med. 2015; 32: 972-979. doi: 10.1111/dme.12717
26. Bjornstad P, Laffel L, Tamborlane WV, Simons G, Hantel S, von Eynatten M, George J, Marquard J, Cherney DZI. Acute effect of empagliflozin on fractional excretion of sodium and eGFR in youth with type 2 diabetes. Diabetes Care. 2018; 41: e129-e130.
27. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996; 49: 1774-1777.
28. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest. 2001; 107: 217-224. doi: 10.1172/JCI10963
29. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol. 2003; 14: 530-537.
30. Laamarti MA, Bell PD, Lapointe JY. Transport and regulatory properties of the apical Na-K-2Cl cotransporter of macula densa cells. Am J Physiol. 1998; 275: F703-F709. doi: 10.1152/ajprenal.1998.275.5.F703
31. Lapointe JY, Bell PD, Cardinal J. Direct evidence for apical Na+: 2Cl-: K+ cotransport in macula densa cells. Am J Physiol. 1990; 258(5 pt 2): F1466-F1469. doi: 10.1152/ajprenal.1990.258.5.F1466
32. Peti-Peterdi J, Bell PD. Regulation of macula densa Na: H exchange by angiotensin II. Kidney Int. 1998; 54: 2021-2028. doi: 10.1046/j.1523-1755. 1998.00200.x
33. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017; 60: 215-225. doi: 10.1007/s00125-016-4157-3
34. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-To-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 610-621. doi: 10.1016/S2213-8587(17)30182-1
35. Skrtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014; 57: 2599-2602. doi: 10.1007/s00125-014-3396-4
36. Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018; 93: 231-244. doi: 10.1016/j.kint. 2017.06.017
37. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017; 28: 368-375. doi: 10.1681/ASN. 2016030278
38. Kovacs G, Komlosi P, Fuson A, Peti-Peterdi J, Rosivall L, Bell PD. Neuronal nitric oxide synthase: its role and regulation in macula densa cells. J Am Soc Nephrol. 2003; 14: 2475-2483.
39. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994; 94: 2504-2510. doi: 10.1172/JCI117620
40. Thomson SC, Deng A, Komine N, Hammes JS, Blantz RC, Gabbai FB. Early diabetes as a model for testing the regulation of juxtaglomerular NOS I. Am J Physiol Renal Physiol. 2004; 287: F732-F738. doi: 10.1152/ajprenal.00340.2003
41. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest. 2001; 107: 889-898. doi: 10.1172/JCI10228
42. Cherney DZ, Miller JA, Scholey JW, Bradley TJ, Slorach C, Curtis JR, Dekker MG, Nasrallah R, Hebert RL, Sochett EB. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes. 2008; 57: 688-695. doi: 10.2337/db07-1230
43. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, Hebert RL, Lai V, Scholey JW, Sochett EB. Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol. 2012; 303: R710-R718. doi: 10.1152/ajpregu.00286.2012
44. Ren Y, Arima S, Carretero OA, Ito S. Possible role of adenosine in macula densa control of glomerular hemodynamics. Kidney Int. 2002; 61: 169-176. doi: 10.1046/j.1523-1755.2002.00093.x
45. Thomson S, Bao D, Deng A, Vallon V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J Clin Invest. 2000; 106: 289-298. doi: 10.1172/JCI8761
46. Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol. 2001; 21: 937-942.
47. Brown R, Ollerstam A, Johansson B, Skott O, Gebre-Medhin S, Fredholm B, Persson AE. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2001; 281: R1362-R1367. doi: 10.1152/ajpregu.2001. 281.5.R1362
48. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, et al. Effects of BG9719 (CVT-124), an A1-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol. 2000; 35: 56-59.
49. Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y, Bjornstad P, Lai V, Tse J, Cham L, et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am J Physiol Renal Physiol. 2018; 314: F412-F422. doi: 10.1152/ajprenal. 00445.2017
50. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018; 94: 26-39. doi: 10.1016/j.kint.2017.12.027